Reviva Pharmaceuticals Holdings Inc (RVPH)
1.265
-0.02
(-1.17%)
USD |
NASDAQ |
Jun 28, 16:00
1.27
0.00 (0.00%)
After-Hours: 20:00
Reviva Pharmaceuticals Holdings SG&A Expense (Quarterly): 2.138M for March 31, 2024
SG&A Expense (Quarterly) Chart
Historical SG&A Expense (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 2.138M |
December 31, 2023 | 1.512M |
September 30, 2023 | 1.992M |
June 30, 2023 | 3.079M |
March 31, 2023 | 1.501M |
December 31, 2022 | 1.476M |
September 30, 2022 | 1.257M |
June 30, 2022 | 1.005M |
March 31, 2022 | 1.620M |
Date | Value |
---|---|
December 31, 2021 | 1.302M |
September 30, 2021 | 1.054M |
June 30, 2021 | 1.416M |
March 31, 2021 | 1.481M |
December 31, 2020 | 0.5267M |
November 30, 2020 | |
September 30, 2020 | 0.5113M |
June 30, 2020 | 0.7409M |
March 31, 2020 | 0.347M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Quarterly) Range, Past 5 Years
0.347M
Minimum
Mar 2020
3.079M
Maximum
Jun 2023
1.350M
Average
1.416M
Median
Jun 2021
SG&A Expense (Quarterly) Benchmarks
AbbVie Inc | 3.315B |
Bristol-Myers Squibb Co | 2.367B |
NovaBay Pharmaceuticals Inc | 3.346M |
Palatin Technologies Inc | 2.033M |
iBio Inc | 2.722M |